Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Pieris Pharmaceuticals nets $26.3mm in IPO

Executive Summary

Pieris Pharmaceuticals Inc. netted $26.3mm in its IPO of 10.3mm shares at $2.75 (including partial exercise of the over-allotment option). Pieris is focused on discovering and developing its class of anticalin biotherapeutics for diseases with high unmet medical needs.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Drug Discovery Tools
    • Large Molecule
Deal Status
  • Final
Deal Type
  • Financing
    • IPO

Related Companies